Cancer Institute A national cancer institute
designated cancer center

Willard ("Bill") E. Fee, Jr.

Publication Details

  • CHEMOTHERAPY AS A SUBSTITUTE FOR SURGERY IN THE TREATMENT OF ADVANCED RESECTABLE HEAD AND NECK-CANCER - A REPORT FROM THE NORTHERN-CALIFORNIA-ONCOLOGY-GROUP CANCER Jacobs, C., Goffinet, D. R., Goffinet, L., Kohler, M., Fee, W. E. 1987; 60 (6): 1178-1183

    Abstract:

    This trial determines the feasibility for patients with resectable Stages III/IV head and neck cancer who achieved a complete response to induction chemotherapy of eliminating surgery from their treatment program. Thirty patients were treated with three cycles of cisplatin and 5-fluorouracil (5-FU), followed by reendoscopy and biopsy. Twelve patients achieved a complete pathologic response at the primary and received radiation (interstitial and/or external beam) only. The remainder underwent surgical resection and postoperative radiation. At 2 years, the relapse-free survival was 52%, and the survival was 53% for the entire group. For the 12 complete responders who had surgery eliminated, the relapse-free survival was 60%, and the survival was 70%. This pilot study suggests that for patients with resectable disease who achieve a complete pathologic response to induction chemotherapy at their primary, it is feasible to omit surgery and treat with primary radiation without compromise in survival. This approach warrants further study in a randomized trial.

    View details for Web of Science ID A1987J841700003

    View details for PubMedID 3304610

Stanford Medicine Resources:

Footer Links: